CoChat
Sign Up
Cited by 15

The DOI matches its Crossref record.

14 Treatment of chronic myeloid leukaemia: some topical questions

Goldman, John M.·1997·Baillière's Clinical Haematology
DOI 10.1016/s0950-3536(97)80015-7
Open this paper in CoChat — free account

Abstract

The treatment of chronic myeloid leukaemia has become extremely complex in recent years. Busulphan has been displaced by hydroxyurea where rapid control of the leukocyte count is required. It is generally accepted that interferon-alpha (IFN-alpha) prolongs life for those who achieve a major or complete cytogenetic response and it may also prolong life for those who achieve only a haematological response. Thus routinely most newly diagnosed patients are started on treatment with IFN-alpha alone or in combination with other agents and this agent is continued if possible for 2 or more years. Because allografting is the only way of curing patients with CML, those under the age of 50 or 60 years who have HLA-identical siblings should be offered treatment by allogeneic haemopoietic stem cell transplantation; however, the risks of morbidity and mortality remain appreciable. Transplants with stem cells from phenotypically HLA-matched donors should also be considered for younger patients. The role of autografting is not yet clearly established; a series of controlled studies comparing autografting with IFN-alpha have therefore been activated. Because patients usually retain in their blood and marrow substantial numbers of Ph-negative stem cells a variety of methods designed to favour collection in vivo or isolation in vitro of Ph-negative stem cells are currently under investigation. To integrate these different approaches to treating patients with CML in chronic phase a variety of al…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0950-3536(97)80015-7

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 68

  1. Allan, 1995, Results of the Medical Research Council randomised multicentre trial of interferon alpha nl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response, Lancet, 345, 1392, 10.1016/S0140-6736(95)92596-1 · DOI
  2. Anasetti, 1992, Marrow transplantation from unrelated donors for treatment of chronic myeloid leukemia, Experimental Hematology, 20, 830
  3. Antonelli, 1991, Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations, Journal of Infectious Diseases, 163, 882, 10.1093/infdis/163.4.882 · DOI
  4. Arcese, 1993, Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia, Blood, 82, 3211, 10.1182/blood.V82.10.3211.3211 · DOI
  5. Baer, 1992, Interferon-α therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia, British Journal of Haematology, 81, 167, 10.1111/j.1365-2141.1992.tb08202.x · DOI
  6. Barnett, 1994, Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study, Blood, 84, 724, 10.1182/blood.V84.3.724.724 · DOI
  7. Beatty, 1991, Marrow transplantation from HLA-matched unrelated donors for treatment of hematological malignancies, Transplantation, 51, 443, 10.1097/00007890-199102000-00034 · DOI
  8. Beelen, 1995, Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant out come, Blood, 85, 2981, 10.1182/blood.V85.10.2981.bloodjournal85102981 · DOI
  9. Bhatia, 1997, Autologous transplantation therapy for chronic myelogenous leukemia, Blood, 89, 2623, 10.1182/blood.V89.8.2623 · DOI
  10. Brito-Babapulle, 1989, Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have finite capacity for maintaining haemopoiesis, British Journal of Haematology, 73, 76, 10.1111/j.1365-2141.1989.tb00223.x · DOI
  11. Carella, 1996, High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia, Bone Marrow Transplantation, 17, 201
  12. Carella, 1997, Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia, Journal of Clinical Oncology, 15, 1575, 10.1200/JCO.1997.15.4.1575 · DOI
  13. Clift, 1993, Treatment of chronic myelogenous leukemia by marrow transplantation, Blood, 82, 1954, 10.1182/blood.V82.7.1954.1954 · DOI
  14. CML Trialists' Collaborative Group (in press) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Journal of National Cancer Institute.
  15. Cross, 1993, Competitive PCR to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation, Blood, 82, 1929, 10.1182/blood.V82.6.1929.1929 · DOI
  16. Cullis, 1992, Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse following allogeneic bone marrow transplantation, Blood, 79, 1379, 10.1182/blood.V79.5.1379.1379 · DOI
  17. Cullis, 1992, Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of busulphan alone for re-conditioning, British Journal of Haematology, 80, 33, 10.1111/j.1365-2141.1992.tb06397.x · DOI
  18. Daley, 1993, Autologous transplants for CML revisited, Experimental Hematology, 21, 734
  19. De Fabritiis, 1990, Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment may necessitate delay in harvesting marrow cells for autografting, Bone Marrow Transplantation, 6, 247
  20. Delmer, 1992, Pregnancy during myelosuppressive treatment for chronic myelogenous leukaemia, British Journal of Haematology, 82, 781, 10.1111/j.1365-2141.1992.tb06968.x · DOI
  21. Derderian, 1993, Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response and prognosis, American Journal of Medicine, 94, 69, 10.1016/0002-9343(93)90122-6 · DOI
  22. Devergie, 1997, European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. Impact of HLA class II matching, Bone Marrow Transplantation, 20, 11, 10.1038/sj.bmt.1700844 · DOI
  23. Drobyski, 1993, Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose, Blood, 82, 2310, 10.1182/blood.V82.8.2310.2310 · DOI
  24. Druker, 1996, Effects of a selective inhibitor of Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nature Medicine, 2, 561, 10.1038/nm0596-561 · DOI · Paper page
  25. Giralt, 1993, Effect of prior interferon-alfa therapy on outcome of allogeneic bone marrow translantation for chronic myelogenous leukaemia, Journal of Clinical Oncology, 11, 1055, 10.1200/JCO.1993.11.6.1055 · DOI
  26. Giralt, 1995, CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation, Blood, 86, 4337, 10.1182/blood.V86.11.4337.bloodjournal86114337 · DOI
  27. Goldman, 1994, Management of chronic myeloid leukaemia, Blood Reviews, 8, 21, 10.1016/0268-960X(94)90004-3 · DOI
  28. Goldman, 1993, Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase, Blood, 82, 2235, 10.1182/blood.V82.7.2235.2235 · DOI
  29. Garin, 1996, Mobilisation with lenograstin of Ph- (Ph neg) blood progenitor cells in patients with chronic myelocytic leukemia, Experimental Hematology, 24, 139
  30. Guilhot, 1997, Interferon alfa-2b combined with cytaribine versus interferon alone chronic myelogenous leukemia, New England Journal of Medicine, 337, 223, 10.1056/NEJM199707243370402 · DOI
  31. Hehlmann, 1993, Randomized camparison of busulfan and hydroxyurea in chronic myelogenous leukemia (CML): prolongation of survival by hydroxyurea, Blood, 82, 398, 10.1182/blood.V82.2.398.398 · DOI
  32. Hehlmann, 1994, Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia, Blood, 84, 4046, 10.1182/blood.V84.12.4064.bloodjournal84124064 · DOI
  33. Hessner, 1995, Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia, Blood, 86, 3987, 10.1182/blood.V86.10.3987.bloodjournal86103987 · DOI
  34. Hochhaus, 1996, Quantification of residual disease in chronic myelogenous leukemia on interferon-α therapy by competitive polymerase chain reaction, Blood, 87, 1549, 10.1182/blood.V87.4.1549.bloodjournal8741549 · DOI
  35. Horowitz, 1996, Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia in first chronic phase, Experimental Hematology, 24, 1143
  36. Hoyle, 1994, Autografting for patients with CML in chronic phase—an update, British Journal of Haematology, 86, 76, 10.1111/j.1365-2141.1994.tb03255.x · DOI
  37. Hughes, 1989, Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow, British Journal of Haematology, 73, 462, 10.1111/j.1365-2141.1989.tb00281.x · DOI
  38. 1994, Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia, New England Journal of Medicine, 330, 820, 10.1056/NEJM199403243301204 · DOI
  39. Kantarjian, 1992, Treatment of chronic myelogeneous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine and granulocytemacrophage colony stimulating factor, Journal of Clinical Oncology, 10, 398, 10.1200/JCO.1992.10.3.398 · DOI
  40. Kantarjian, 1995, Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy, Annals of Internal Medicine, 122, 254, 10.7326/0003-4819-122-4-199502150-00003 · DOI
  41. Kantarjian, 1996, Treatment of chronic myelogenous leukemia: current status and investigational options, Blood, 87, 3069, 10.1182/blood.V87.8.3069.bloodjournal8783069 · DOI
  42. Kolb, 1990, Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients, Blood, 76, 2462, 10.1182/blood.V76.12.2462.2462 · DOI
  43. Kolb, 1995, Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients, Blood, 86, 2041, 10.1182/blood.V86.5.2041.bloodjournal8652041 · DOI
  44. Lin, 1996, Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation, Blood, 87, 4473, 10.1182/blood.V87.10.4473.bloodjournal87104473 · DOI
  45. Lion, 1993, Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia, Lancet, 341, 275, 10.1016/0140-6736(93)92619-5 · DOI
  46. Mackinnon, 1990, Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors, Experimental Hematology, 18, 421
  47. Mackinnon, 1995, Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease, Blood, 86, 1261, 10.1182/blood.V86.4.1261.bloodjournal8641261 · DOI
  48. Marks, 1993, Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years, Annals of Internal Medicine, 119, 207, 10.7326/0003-4819-119-3-199308010-00005 · DOI
  49. McGlave, 1993, Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program, Blood, 81, 543, 10.1182/blood.V81.2.543.543 · DOI
  50. McGlave, 1994, Autologous transplant therapy for chronic myelogenous leukemia prolongs survival: results from eight transplant groups, Lancet, 343, 1486, 10.1016/S0140-6736(94)92589-5 · DOI
  51. Medical Research Council, 1968, Chronic granulocytic leukaemia: Comparison of radiotherapy and busulphan therapy, British Medical Journal, 1, 201, 10.1136/bmj.1.5586.201 · DOI
  52. Mrsic, 1992, Second HLA-identical sibling transplants for leukemia recurrence, Bone Marrow Transplantation, 9, 269
  53. Nathwani, 1993, The management of chronic myeloid leukemia in lymphoid blast crisis, Haematologica, 78, 162
  54. O'Brien, 1994, Autografting in chronic myeloid leukaemia, Blood Reviews, 8, 63, 10.1016/S0268-960X(05)80009-8 · DOI
  55. O'Brien, 1995, Current approaches to hematopoietic stem cell purging in chronic myeloid leukemia, Journal of Clinical Oncology, 13, 541, 10.1200/JCO.1995.13.3.541 · DOI
  56. Ozer, 1993, Blood, 82, 2975, 10.1182/blood.V82.10.2975.2975 · DOI
  57. Reiffers, 1994, Autologous stem cell transplantation in chronic myelogenous leukaemia, Bone Marrow Transplantation, 14, 407
  58. van Rhee, 1994, Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse, Blood, 83, 3377, 10.1182/blood.V83.11.3377.3377 · DOI
  59. Rule, 1996, Intermediate dose busulphan before autografting for advanced phase chronic myeloid leukaemia, British Journal of Haematology, 94, 694, 10.1046/j.1365-2141.1996.00709.x · DOI
  60. Schofield, 1994, Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia, Annals of Internal Medicine, 121, 736, 10.7326/0003-4819-121-10-199411150-00002 · DOI
  61. Simonsson, 1994, Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukaemia (CML), Bone Marrow Transplantation, 14, S55
  62. Spencer, 1995, Cytotoxic T-lymphocyte precursor frequency analysis in bone marrow transplantation with volunteer unrelated donors: value in donor selection, Transplantation, 59, 1, 10.1097/00007890-199505150-00014 · DOI
  63. Spencer, 1995, Chronic myeloid leukaemia—options for therapy, British Journal of Haematology, 91, 2, 10.1111/j.1365-2141.1995.tb05236.x · DOI
  64. Spencer, 1995, Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donor using ex vivo or in vivo T-cell depletion: major prognostic impact of class I identity between donor and recipient, Blood, 86, 3590, 10.1182/blood.V86.9.3590.bloodjournal8693590 · DOI
  65. Talpaz, 1983, Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia, Blood, 62, 1052, 10.1182/blood.V62.3.689.689 · DOI
  66. Talpaz, 1986, Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia, New England Journal of Medicine, 314, 1065, 10.1056/NEJM198604243141701 · DOI
  67. Talpaz, 1991, Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients, Annals of Internal Medicine, 114, 532, 10.7326/0003-4819-114-7-532 · DOI
  68. Thomas, 1986, Marrow transplantation for the treatment of chronic myelogenous leukemia, Annals of Internal Medicine, 104, 155, 10.7326/0003-4819-104-2-155 · DOI

Cited by

See all 15

Metadata

Authors
Goldman, J. M.
Venue
Baillière's Clinical Haematology
Publisher
Elsevier BV
Published
1997-06
Volume
10
Issue
2
Pages
405-421
ISSN
0950-3536
DOI
10.1016/s0950-3536(97)80015-7
Cited by
15
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 14 Treatment of chronic myeloid leukaemia: some topical questions. https://app.cochat.ai/papers/10.1016/s0950-3536(97)80015-7
The paper
Goldman, J. M. (1997). 14 Treatment of chronic myeloid leukaemia: some topical questions. Baillière's Clinical Haematology. https://doi.org/10.1016/s0950-3536(97)80015-7